MovDisordV3, Istex, Curation, bibRecord, 000812

The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease

Identifieur interne : 000812 ( Istex/Curation ); précédent : 000811; suivant : 000813

The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease

Auteurs : J. Eric Ahlskog [États-Unis] ; Ryan J. Uitti [États-Unis] ; Michael K. O'Connor [États-Unis] ; Demetrius M. Maraganore [États-Unis] ; Joseph Y. Matsumoto [États-Unis] ; Kathy F. Stark [États-Unis] ; Margaret F. Turk [États-Unis] ; Omer L. Burnett [États-Unis]

Source :

Movement Disorders [ 0885-3185 ] ; 1999-11.

RBID : ISTEX:8EAD6592CF98902FE2CD4D0353934E761EB627D2

English descriptors

KwdEn :
- Dopamine agonist, Dopamine transporter, Parkinson's disease, Pergolide, SPECT, [123I] β‐CIT.

Abstract

Single‐photon emission computed tomography (SPECT) imaging with the dopamine transporter ligand, [123I] β‐CIT (2β‐carboxymethoxy‐3β‐[4‐iodophenyl] tropane), has been proposed as a means of measuring Parkinson's disease (PD) progression. To be useful in this role, however, [123I] β‐CIT imaging should not be influenced by the medications used to treat PD, including the dopamine agonist drugs such as pergolide. We assessed the effect of adjunctive pergolide administration on [123I] β‐CIT uptake in 12 patients with PD, who were being treated with levodopa, initiating pergolide therapy for motor fluctuations. Patients underwent [123I] β‐CIT imaging at baseline, subsequently while on pergolide therapy (6 weeks), and again 4 weeks after pergolide wash‐out. Uptake in the striatum was averaged for the two sides and expressed as (striatum − occipital)/occipital, with similar calculations for putamen and caudate. Consistent with PD, the patients' mean striatal and putamen uptake ratios at baseline were significantly less (p <0.001) than the mean values from 26 normal control subjects of similar age. During pergolide treatment, the striatal and putamen [123I] β‐CIT uptake ratios were each statistically similar to baseline, although there was a slight trend toward an increased striatal value (8% higher on pergolide; p = 0.105). Caudate [123I] β‐CIT uptake was 11% higher on pergolide therapy (nominal p = 0.042, but not significant when adjusted for multiple comparisons: p = 0.126). After pergolide wash‐out, the striatal, putamen, and caudate uptake ratios did not differ from baseline. Therefore, we found that pergolide therapy did not significantly affect [123I] β‐CIT SPECT imaging but we cannot exclude a small influence.

Url:

https://api.istex.fr/document/8EAD6592CF98902FE2CD4D0353934E761EB627D2/fulltext/pdf

DOI: 10.1002/1531-8257(199911)14:6<940::AID-MDS1005>3.0.CO;2-Y

Links toward previous steps (curation, corpus...)

to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000812

Links to Exploration step

ISTEX:8EAD6592CF98902FE2CD4D0353934E761EB627D2

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease</title>
<author><name sortKey="Ahlskog, J Eric" sort="Ahlskog, J Eric" uniqKey="Ahlskog J" first="J. Eric" last="Ahlskog">J. Eric Ahlskog</name>
<affiliation wicri:level="2"><mods:affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Minnesota</region>
</placeName>
<wicri:cityArea>Department of Neurology, Mayo Clinic, Rochester</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Uitti, Ryan J" sort="Uitti, Ryan J" uniqKey="Uitti R" first="Ryan J." last="Uitti">Ryan J. Uitti</name>
<affiliation wicri:level="2"><mods:affiliation>Department of Neurology, Mayo Clinic, Jacksonville, Florida</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Floride</region>
</placeName>
<wicri:cityArea>Department of Neurology, Mayo Clinic, Jacksonville</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="O Connor, Michael K" sort="O Connor, Michael K" uniqKey="O Connor M" first="Michael K." last="O'Connor">Michael K. O'Connor</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, Mayo Clinic, Rochester, Minnesota, U.S.A.</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Nuclear Medicine, Mayo Clinic, Rochester, Minnesota</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Maraganore, Demetrius M" sort="Maraganore, Demetrius M" uniqKey="Maraganore D" first="Demetrius M." last="Maraganore">Demetrius M. Maraganore</name>
<affiliation wicri:level="2"><mods:affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Minnesota</region>
</placeName>
<wicri:cityArea>Department of Neurology, Mayo Clinic, Rochester</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Matsumoto, Joseph Y" sort="Matsumoto, Joseph Y" uniqKey="Matsumoto J" first="Joseph Y." last="Matsumoto">Joseph Y. Matsumoto</name>
<affiliation wicri:level="2"><mods:affiliation>Department of Neurology, Mayo Clinic, Jacksonville, Florida</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Floride</region>
</placeName>
<wicri:cityArea>Department of Neurology, Mayo Clinic, Jacksonville</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Stark, Kathy F" sort="Stark, Kathy F" uniqKey="Stark K" first="Kathy F." last="Stark">Kathy F. Stark</name>
<affiliation wicri:level="2"><mods:affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Minnesota</region>
</placeName>
<wicri:cityArea>Department of Neurology, Mayo Clinic, Rochester</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Turk, Margaret F" sort="Turk, Margaret F" uniqKey="Turk M" first="Margaret F." last="Turk">Margaret F. Turk</name>
<affiliation wicri:level="2"><mods:affiliation>Department of Neurology, Mayo Clinic, Jacksonville, Florida</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Floride</region>
</placeName>
<wicri:cityArea>Department of Neurology, Mayo Clinic, Jacksonville</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Burnett, Omer L" sort="Burnett, Omer L" uniqKey="Burnett O" first="Omer L." last="Burnett">Omer L. Burnett</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, Mayo Clinic, Jacksonville, Florida, U.S.A.</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Nuclear Medicine, Mayo Clinic, Jacksonville, Florida</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:8EAD6592CF98902FE2CD4D0353934E761EB627D2</idno>
<date when="1999" year="1999">1999</date>
<idno type="doi">10.1002/1531-8257(199911)14:6<940::AID-MDS1005>3.0.CO;2-Y</idno>
<idno type="url">https://api.istex.fr/document/8EAD6592CF98902FE2CD4D0353934E761EB627D2/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000812</idno>
<idno type="wicri:Area/Istex/Curation">000812</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease</title>
<author><name sortKey="Ahlskog, J Eric" sort="Ahlskog, J Eric" uniqKey="Ahlskog J" first="J. Eric" last="Ahlskog">J. Eric Ahlskog</name>
<affiliation wicri:level="2"><mods:affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Minnesota</region>
</placeName>
<wicri:cityArea>Department of Neurology, Mayo Clinic, Rochester</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Uitti, Ryan J" sort="Uitti, Ryan J" uniqKey="Uitti R" first="Ryan J." last="Uitti">Ryan J. Uitti</name>
<affiliation wicri:level="2"><mods:affiliation>Department of Neurology, Mayo Clinic, Jacksonville, Florida</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Floride</region>
</placeName>
<wicri:cityArea>Department of Neurology, Mayo Clinic, Jacksonville</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="O Connor, Michael K" sort="O Connor, Michael K" uniqKey="O Connor M" first="Michael K." last="O'Connor">Michael K. O'Connor</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, Mayo Clinic, Rochester, Minnesota, U.S.A.</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Nuclear Medicine, Mayo Clinic, Rochester, Minnesota</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Maraganore, Demetrius M" sort="Maraganore, Demetrius M" uniqKey="Maraganore D" first="Demetrius M." last="Maraganore">Demetrius M. Maraganore</name>
<affiliation wicri:level="2"><mods:affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Minnesota</region>
</placeName>
<wicri:cityArea>Department of Neurology, Mayo Clinic, Rochester</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Matsumoto, Joseph Y" sort="Matsumoto, Joseph Y" uniqKey="Matsumoto J" first="Joseph Y." last="Matsumoto">Joseph Y. Matsumoto</name>
<affiliation wicri:level="2"><mods:affiliation>Department of Neurology, Mayo Clinic, Jacksonville, Florida</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Floride</region>
</placeName>
<wicri:cityArea>Department of Neurology, Mayo Clinic, Jacksonville</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Stark, Kathy F" sort="Stark, Kathy F" uniqKey="Stark K" first="Kathy F." last="Stark">Kathy F. Stark</name>
<affiliation wicri:level="2"><mods:affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Minnesota</region>
</placeName>
<wicri:cityArea>Department of Neurology, Mayo Clinic, Rochester</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Turk, Margaret F" sort="Turk, Margaret F" uniqKey="Turk M" first="Margaret F." last="Turk">Margaret F. Turk</name>
<affiliation wicri:level="2"><mods:affiliation>Department of Neurology, Mayo Clinic, Jacksonville, Florida</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Floride</region>
</placeName>
<wicri:cityArea>Department of Neurology, Mayo Clinic, Jacksonville</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Burnett, Omer L" sort="Burnett, Omer L" uniqKey="Burnett O" first="Omer L." last="Burnett">Omer L. Burnett</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, Mayo Clinic, Jacksonville, Florida, U.S.A.</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Nuclear Medicine, Mayo Clinic, Jacksonville, Florida</wicri:regionArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>John Wiley & Sons, Inc.</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="1999-11">1999-11</date>
<biblScope unit="vol">14</biblScope>
<biblScope unit="issue">6</biblScope>
<biblScope unit="page" from="940">940</biblScope>
<biblScope unit="page" to="946">946</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">8EAD6592CF98902FE2CD4D0353934E761EB627D2</idno>
<idno type="DOI">10.1002/1531-8257(199911)14:6<940::AID-MDS1005>3.0.CO;2-Y</idno>
<idno type="ArticleID">MDS1005</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dopamine agonist</term>
<term>Dopamine transporter</term>
<term>Parkinson's disease</term>
<term>Pergolide</term>
<term>SPECT</term>
<term>[123I] β‐CIT</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Single‐photon emission computed tomography (SPECT) imaging with the dopamine transporter ligand, [123I] β‐CIT (2β‐carboxymethoxy‐3β‐[4‐iodophenyl] tropane), has been proposed as a means of measuring Parkinson's disease (PD) progression. To be useful in this role, however, [123I] β‐CIT imaging should not be influenced by the medications used to treat PD, including the dopamine agonist drugs such as pergolide. We assessed the effect of adjunctive pergolide administration on [123I] β‐CIT uptake in 12 patients with PD, who were being treated with levodopa, initiating pergolide therapy for motor fluctuations. Patients underwent [123I] β‐CIT imaging at baseline, subsequently while on pergolide therapy (6 weeks), and again 4 weeks after pergolide wash‐out. Uptake in the striatum was averaged for the two sides and expressed as (striatum − occipital)/occipital, with similar calculations for putamen and caudate. Consistent with PD, the patients' mean striatal and putamen uptake ratios at baseline were significantly less (p <0.001) than the mean values from 26 normal control subjects of similar age. During pergolide treatment, the striatal and putamen [123I] β‐CIT uptake ratios were each statistically similar to baseline, although there was a slight trend toward an increased striatal value (8% higher on pergolide; p = 0.105). Caudate [123I] β‐CIT uptake was 11% higher on pergolide therapy (nominal p = 0.042, but not significant when adjusted for multiple comparisons: p = 0.126). After pergolide wash‐out, the striatal, putamen, and caudate uptake ratios did not differ from baseline. Therefore, we found that pergolide therapy did not significantly affect [123I] β‐CIT SPECT imaging but we cannot exclude a small influence.</div>
</front>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000812 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 000812 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Istex
   |étape=   Curation
   |type=    RBID
   |clé=     ISTEX:8EAD6592CF98902FE2CD4D0353934E761EB627D2
   |texte=   The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease

The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri